Preclinical News and Research

RSS
TPP and University of Edinburgh collaborate on development of novel pre-clinical intellectual property

TPP and University of Edinburgh collaborate on development of novel pre-clinical intellectual property

Advanced Life Sciences scientific publication demonstrates triterpenoids' potential as anticancer agents

Advanced Life Sciences scientific publication demonstrates triterpenoids' potential as anticancer agents

Amsterdam Molecular first half 2010 net loss in line with last year

Amsterdam Molecular first half 2010 net loss in line with last year

Cell Therapy Foundation analysis calls for funding in medical research

Cell Therapy Foundation analysis calls for funding in medical research

HUYA announces strategic partnership with School of Pharmaceutical Sciences at Sun Yat-sen University

HUYA announces strategic partnership with School of Pharmaceutical Sciences at Sun Yat-sen University

Nanotherapeutics files NanoDTPA IND for treatment of radiation exposure

Nanotherapeutics files NanoDTPA IND for treatment of radiation exposure

Bend Research granted patent for making solid amorphous dispersions of drugs with SDD technology

Bend Research granted patent for making solid amorphous dispersions of drugs with SDD technology

Ricerca Biosciences completes purification of an API under cGMP controls

Ricerca Biosciences completes purification of an API under cGMP controls

AgeneBio receives grant to develop neural stabilizer therapy for amnestic mild cognitive impairment

AgeneBio receives grant to develop neural stabilizer therapy for amnestic mild cognitive impairment

Lotus Pharmaceuticals initiates R-Bambuterol Clinical Trial I on-schedule

Lotus Pharmaceuticals initiates R-Bambuterol Clinical Trial I on-schedule

NeoPharm second-quarter net loss decreases to $0.8 million

NeoPharm second-quarter net loss decreases to $0.8 million

Alexza Pharmaceuticals licenses Staccato nicotine technology to Cypress Bioscience

Alexza Pharmaceuticals licenses Staccato nicotine technology to Cypress Bioscience

FDA approves Chelsea Therapeutics' Phase II protocol for CH-4051 antifolate in rheumatoid arthritis

FDA approves Chelsea Therapeutics' Phase II protocol for CH-4051 antifolate in rheumatoid arthritis

Phase 1 CRLX101 clinical study paves way for promising innovations in cancer therapy: Cerulean Pharma

Phase 1 CRLX101 clinical study paves way for promising innovations in cancer therapy: Cerulean Pharma

Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity

Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity

Researchers identify novel approach to decrease glioblastoma multiforme recurrence

Researchers identify novel approach to decrease glioblastoma multiforme recurrence

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

FDA clears PROLOR Biotech's Phase II clinical trial of hGH-CTP

FDA clears PROLOR Biotech's Phase II clinical trial of hGH-CTP

Raptor Pharmaceutical updates on cysteamine bitartrate Phase 3 clinical trial in cystinosis patients

Raptor Pharmaceutical updates on cysteamine bitartrate Phase 3 clinical trial in cystinosis patients

Epilepsy Therapy Project, EF announce recipients of New Therapy Grants Program

Epilepsy Therapy Project, EF announce recipients of New Therapy Grants Program

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.